Dyne Therapeutics, Inc. (DYN)
NMS · Healthcare · Biotechnology
$18.21
-1.14%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$3.40B
Shares Outstanding
186.7M
Exchange
NMS
Currency
USD
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (113.9M) | (116.1M) | (125.3M) | (181.7M) |
| Net Income | (108.0M) | (112.0M) | (120.9M) | (178.6M) |
| Diluted EPS | $-0.76 | $-0.76 | $-0.73 | $-1.08 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (171.0M) | (242.2M) | (343.9M) | (468.2M) |
| Net Income | (168.1M) | (235.9M) | (317.4M) | (446.2M) |
| Diluted EPS | $-3.23 | $-3.95 | $-3.37 | N/A |